Given the promising data from this study, Neurogastrx is looking to launch a larger Phase 2 study in 2025
S6 show that both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk (13% and 14%, respectively) as compared with placebo and DPP-4 inhibitors (11% and 12%, respectively), although the difference in risks was significant for SGLT-2 vs DPP-4 inhibitors only
To test whether any of these exopolymers constitutes AEP, deletion mutants for each exopolymer, as well as a triple mutant defective for all three polymers, were tested for their ability to secrete AEP
Research findings: Studies show kisspeptin administration enhances brain responses to sexual images and romantic scenarios
can we separate the good from the bad
In contrast, studies of GLP-1RAs directed specifically at understanding their impact in pulmonary diseases in patients without obesity or T2DM remain limited